Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Acquires 3,240 Shares of Stock

STAAR Surgical Company (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 3,240 shares of the stock in a transaction on Thursday, January 8th. The stock was acquired at an average price of $21.94 per share, with a total value of $71,085.60. Following the completion of the acquisition, the insider owned 15,426,144 shares of the company’s stock, valued at $338,449,599.36. This represents a 0.02% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, January 7th, Broadwood Partners, L.P. purchased 66,467 shares of STAAR Surgical stock. The stock was bought at an average price of $22.00 per share, with a total value of $1,462,274.00.
• On Tuesday, January 6th, Broadwood Partners, L.P. bought 336,946 shares of STAAR Surgical stock. The stock was purchased at an average cost of $21.62 per share, with a total value of $7,284,772.52.
• On Wednesday, November 19th, Broadwood Partners, L.P. acquired 309,132 shares of STAAR Surgical stock. The stock was acquired at an average cost of $26.42 per share, for a total transaction of $8,167,267.44.
• On Friday, November 21st, Broadwood Partners, L.P. purchased 797,486 shares of STAAR Surgical stock. The stock was acquired at an average cost of $27.86 per share, for a total transaction of $22,217,959.96.
• On Thursday, November 20th, Broadwood Partners, L.P. bought 393,382 shares of STAAR Surgical stock. The shares were bought at an average cost of $27.14 per share, for a total transaction of $10,676,387.48.

STAAR Surgical Trading Up 1.4%

Shares of STAA stock traded up $0.31 during trading on Thursday, hitting $22.50. The company’s stock had a trading volume of 2,126,114 shares, compared to its average volume of 1,497,022. The business has a fifty day moving average of $25.09 and a 200-day moving average of $24.37. STAAR Surgical Company has a 52 week low of $13.50 and a 52 week high of $30.81. The company has a market cap of $1.12 billion, a PE ratio of -11.54 and a beta of 1.00.

Analyst Ratings Changes

Several equities analysts recently commented on STAA shares. Wells Fargo & Company upped their price objective on STAAR Surgical from $28.00 to $30.75 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Canaccord Genuity Group upped their price objective on shares of STAAR Surgical from $28.00 to $30.75 and gave the company a “hold” rating in a report on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of STAAR Surgical in a research note on Wednesday, October 8th. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday. Finally, BTIG Research reaffirmed a “neutral” rating on shares of STAAR Surgical in a research note on Tuesday. Ten equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $23.42.

Institutional Trading of STAAR Surgical

Institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in STAAR Surgical by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock valued at $518,000 after purchasing an additional 1,267 shares during the period. Jones Financial Companies Lllp increased its position in shares of STAAR Surgical by 211,284.0% during the first quarter. Jones Financial Companies Lllp now owns 158,538 shares of the medical instruments supplier’s stock valued at $2,795,000 after buying an additional 158,463 shares during the period. Goldman Sachs Group Inc. increased its position in shares of STAAR Surgical by 33.4% during the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock valued at $9,606,000 after buying an additional 136,390 shares during the period. Caxton Associates LLP bought a new position in STAAR Surgical in the first quarter worth about $1,051,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in STAAR Surgical by 11.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock valued at $2,175,000 after acquiring an additional 12,841 shares in the last quarter. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.